We are international
Donate
• treatment options TEXT SIZE   
Clinical Trials

Kyprolis™

Kyprolis™ (carfilzomib) is a next-generation proteasome inhibitor. Kyprolis is FDA-approved for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies, including bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease progression on or within 60 days of the completion of the last therapy.

General Information
Clinical Trials
Webcasts
Blogs and Press Releases
Links
The ENDEAVOR Trial
A Fact Sheet
Phase III Study with Carfilzomib & Dexamethasone vs Velcade & Dexamethasone for Relapsed MM Patients. Sites actively opening, so call the Hotline for the most up-to-date listings.
The ENDEAVOR TRIAL on clinicaltrials.gov

Open Carfilzomib Trials